Vanguard Group’s Moleculin Biotech MBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $51.5K | Buy |
15,544
+5,947
| +62% | +$55.4K | ﹤0.01% | 4243 |
|
|
2025
Q3 | $127K | Buy |
9,597
+8,360
| +676% | +$113K | ﹤0.01% | 4193 |
|
|
2025
Q2 | $9.34K | Hold |
1,237
| – | – | ﹤0.01% | 4264 |
|
|
2025
Q1 | $30.1K | Hold |
1,237
| – | – | ﹤0.01% | 4227 |
|
|
2024
Q4 | $52.6K | Sell |
1,237
-1,619
| -57% | -$98.1K | ﹤0.01% | 4211 |
|
|
2024
Q3 | $203K | Sell |
2,856
-521
| -15% | -$37.5K | ﹤0.01% | 4142 |
|
|
2024
Q2 | $297K | Buy |
3,377
+365
| +12% | +$42.2K | ﹤0.01% | 4101 |
|
|
2024
Q1 | $445K | Buy |
3,012
+132
| +5% | +$28.1K | ﹤0.01% | 4046 |
|
|
2023
Q4 | $927K | Hold |
2,880
| – | – | ﹤0.01% | 3851 |
|
|
2023
Q3 | $462K | Hold |
2,880
| – | – | ﹤0.01% | 4072 |
|
|
2023
Q2 | $625K | Hold |
2,880
| – | – | ﹤0.01% | 4056 |
|
|
2023
Q1 | $1.04M | Hold |
2,880
| – | – | ﹤0.01% | 3905 |
|
|
2022
Q4 | $1.14M | Buy |
2,880
+1
| +0% | +$422 | ﹤0.01% | 3861 |
|
|
2022
Q3 | $1.14M | Hold |
2,879
| – | – | ﹤0.01% | 3961 |
|
|
2022
Q2 | $1.56M | Hold |
2,879
| – | – | ﹤0.01% | 3920 |
|
|
2022
Q1 | $1.92M | Sell |
2,879
-22
| -0.8% | -$12.6K | ﹤0.01% | 3975 |
|
|
2021
Q4 | $2.02M | Buy |
2,901
+93
| +3% | +$82.5K | ﹤0.01% | 4036 |
|
|
2021
Q3 | $3.16M | Buy |
2,808
+15
| +0.5% | +$17.5K | ﹤0.01% | 3892 |
|
|
2021
Q2 | $3.84M | Buy |
2,793
+1,544
| +124% | +$2.11M | ﹤0.01% | 3726 |
|
|
2021
Q1 | $1.91M | Buy |
1,249
+986
| +375% | +$1.81M | ﹤0.01% | 3870 |
|
|
2020
Q4 | $472K | Sell |
263
-15
| -5% | -$26.6K | ﹤0.01% | 3961 |
|
|
2020
Q3 | $509K | Sell |
278
-409
| -60% | -$869K | ﹤0.01% | 3813 |
|
|
2020
Q2 | $1.5M | Sell |
687
-491
| -42% | -$1.16M | ﹤0.01% | 3517 |
|
|
2020
Q1 | $1.62M | Buy |
1,178
+22
| +2% | +$37.5K | ﹤0.01% | 3356 |
|
|
2019
Q4 | $2.38M | Sell |
1,156
-1
| -0.1% | -$2.34K | ﹤0.01% | 3400 |
|
|
2019
Q3 | $2.89M | Sell |
1,157
-34
| -3% | -$87.8K | ﹤0.01% | 3321 |
|
|
2019
Q2 | $3.35M | Buy |
1,191
+836
| +235% | +$2.27M | ﹤0.01% | 3307 |
|
|
2019
Q1 | $647K | Buy |
355
+49
| +16% | +$146K | ﹤0.01% | 3727 |
|
|
2018
Q4 | $716K | Buy |
306
+10
| +3% | +$28.7K | ﹤0.01% | 3656 |
|
|
2018
Q3 | $1.07M | Buy |
296
+2
| +0.7% | +$7.54K | ﹤0.01% | 3702 |
|
|
2018
Q2 | $1.18M | Buy |
294
+51
| +21% | +$209K | ﹤0.01% | 3645 |
|
|
2018
Q1 | $984K | Buy |
243
+39
| +19% | +$169K | ﹤0.01% | 3651 |
|
|
2017
Q4 | $855K | Buy |
204
+15
| +8% | +$64.9K | ﹤0.01% | 3643 |
|
|
2017
Q3 | $1.02M | Buy |
189
+39
| +26% | +$206K | ﹤0.01% | 3587 |
|
|
2017
Q2 | $631K | Buy |
150
+33
| +28% | +$71.8K | ﹤0.01% | 3683 |
|
|
2017
Q1 | $309K | Buy |
117
+109
| +1,363% | +$381K | ﹤0.01% | 3834 |
|
|
2016
Q4 | $41K | Buy |
+8
| New | +$53.6K | ﹤0.01% | 4044 |
|
Other funds holding MBRX
TRCT
EI
PWPS
NFSG
Vanguard Group's MBRX Position: Q4 2025 in Review
Vanguard Group increased its Moleculin Biotech (MBRX) stake by 62% in Q4 2025, buying an estimated $55.4K and bringing the position to 15,544 shares worth $51.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4243.
Vanguard Group first reported a position in MBRX in Q4 2016 and has held it in 37 quarters since. The position peaked at $3.84M in Q2 2021. 17 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.
- Vanguard Group held 15,544 shares of Moleculin Biotech worth $51.5K as of Q4 2025.
- Vanguard Group bought 5,947 Moleculin Biotech shares in Q4 2025, an estimated $55.4K.
- Moleculin Biotech made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4243 holding.
- Vanguard Group first reported a position in Moleculin Biotech in Q4 2016 and has held it in 37 quarters since.
- Vanguard Group's Moleculin Biotech position peaked at $3.84M in Q2 2021.
- 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.